DXVX is showing strength. The news that the government will invest 400 billion KRW in the microbiome industry is interpreted as drawing attention to DXVX, which is developing microbiome-based diabetes and obesity treatments.
As of 10:27 AM on the 5th, DXVX is trading at 7,080 KRW, up 5.35% compared to the previous day.
On the previous day, Kim Hyung-cheol, a Bio PD at the Korea Institute for Advancement of Technology under the Ministry of Trade, Industry and Energy, announced plans to carry out a cross-ministerial "Microbiome Technology Development Project to Overcome Human Diseases" with a budget of around 400 billion KRW over eight years from 2025 to 2032. The participating ministries include the Ministry of Science and ICT, Ministry of Health and Welfare, Ministry of Trade, Industry and Energy, Korea Disease Control and Prevention Agency, among six others.
The microbiome is a term combining microorganisms and ecosystem, referring to the tens of trillions of microorganisms and their genes present in the body. Among these, beneficial types are increasingly being used in pharmaceuticals and health functional foods.
DXVX is developing microbiome-based diabetes and obesity treatments. Together with the Kori Group, they are conducting clinical research using innovative technology and multi-omics analysis on healthy individuals, people with diabetes, and obese individuals, comparing dietary and lifestyle habits.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
